Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Income from Continuing Operations (2023 - 2025)

Contineum Therapeutics has reported Income from Continuing Operations over the past 3 years, most recently at 15105000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 15105000.0 for Q4 2025, down 3.71% from a year ago — trailing twelve months through Dec 2025 was 59813000.0 (down 41.54% YoY), and the annual figure for FY2025 was 59813000.0, down 41.54%.
  • Income from Continuing Operations for Q4 2025 was 15105000.0 at Contineum Therapeutics, down from 12975000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for CTNM hit a ceiling of 41564000.0 in Q2 2023 and a floor of 15873000.0 in Q2 2025.
  • Median Income from Continuing Operations over the past 3 years was 9638000.0 (2024), compared with a mean of 6613500.0.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 121.68% in 2024 and later decreased 3.71% in 2025.
  • Contineum Therapeutics' Income from Continuing Operations stood at 7780000.0 in 2023, then crashed by 87.21% to 14565000.0 in 2024, then dropped by 3.71% to 15105000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 15105000.0 (Q4 2025), 12975000.0 (Q3 2025), and 15873000.0 (Q2 2025) per Business Quant data.